Phase 1 dose-escalation study of CDX-1140

Trial Profile

Phase 1 dose-escalation study of CDX-1140

Phase of Trial: Phase I

Latest Information Update: 12 Dec 2016

At a glance

  • Drugs CDX 1140 (Primary)
  • Indications Cancer; Lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Dec 2016 New trial record
    • 05 Dec 2016 According to Celldex Therapeutics media release, company plans to initiate this study in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top